Virtus Pharmaceuticals Inc. – a specialty niche pharmaceutical company and part of the Linden Capital Partners portfolio – announced it launched Prometrium (Progesterone, USP Capsules), the company’s first branded product.
Dupilumab, Regeneron/Sanofi Dupilumab is the first systemic therapy to demonstrate positive Phase III results in patients with moderate-to-severe atopic dermatitis. The serious, chronic inflammatory skin disease is marked by widespread rash, itching and associated psychosocial comorbidities. Dupilumab inhibits interleukin-4 and interleukin-13, which are small anti-inflammatory proteins secreted by cells that are thought to play a […]
IMS analysis revealed that lower-cost copies of complex biotechnology drugs could save the United States and Europe’s five top markets as much as €98 billion ($110 billion) by 2020.
Immunocore was recognized as SCRIP Awards 2015’s Biotech of the Year. Immunocore is a world-leading biotech company developing novel T cell receptor (TCR) based biological drugs for the treatment of cancer, viral infections and autoimmune disease.
To reach payer audiences, companies have to focus far less on promotional tactics and show the value of their products.
Frank X. Powers and Lorna Weir have teamed up to form a new venture – Elevate Healthcare Marketing. The reason why, these executives explain in their launch press release, is “Because they believe that truly helping clients raise the value of their offerings in the dynamic world of healthcare now demands a different type of collaboration.”
Ogilvy CommonHealth Worldwide, the health behavior change specialists of Ogilvy & Mather and a WPP company, has launched the Ogilvy CommonHealth Marketing Cloud platform. The first of its kind, data-driven offering is anticipated to help marketers better understand, reach and engage with physicians on an individual level while sharing news of its newly formed partnership with Medikly, which is a leading provider of physician engagement solutions.
Indianapolis-based Eli Lilly and Company is on a roll, announcing that between 2014 and 2023, it may launch 20 new products.
Novartis’s heart failure drug Entresto will be subjected to a battery of new trials as the Swiss drugmaker seeks to boost the medicine after a disappointing introduction.
Startup Homology Medicines Launches With $43 Million Series A, To Be Led By Three Former Shire Execs May 2, 2016By Mark Terry, BioSpace.com Breaking News Staff Lexington, Mass.-based Homology Medicines launched today with a $43.5 million Series A preferred stock financing. The round was co-led by 5AM Ventures and ARCH Venture Partners. They […]